Severe Hemophilia A
33
6
9
17
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
15 trials with published results (45%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
9.1%
3 terminated out of 33 trials
85.0%
-1.6% vs benchmark
64%
21 trials in Phase 3/4
88%
15 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 17 completed trials
Clinical Trials (33)
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A
Palliative Care Needs of Children With Rare Diseases and Their Families
Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A
Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A
Bone Microarchitecture in Men With Hemophilia
Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study
A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)
Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII